U.S. markets close in 3 hours 24 minutes

Altimmune, Inc. (ALT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
15.65+0.09 (+0.58%)
As of 12:36PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close15.56
Open15.75
Bid15.54 x 1400
Ask15.62 x 900
Day's Range15.26 - 16.14
52 Week Range7.80 - 35.10
Volume344,510
Avg. Volume1,344,531
Market Cap600.91M
Beta (5Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-1.90
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJan 20, 2017
1y Target Est44.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Altimmune, Inc. (ALT) Soars 16.5%: Is Further Upside Left in the Stock?
    Zacks

    Altimmune, Inc. (ALT) Soars 16.5%: Is Further Upside Left in the Stock?

    Altimmune, Inc. (ALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

  • Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers
    GlobeNewswire

    Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers

    Weight loss of 5.4% achieved at 6 weeks of treatment with 1.8 mg once weekly dose, surpassing the 2% pre-established treatment targetAscending multi-dose regimen well-tolerated without necessity for dose titration Trial continuing with 12-week data expected in Q3 2021Company plans to file an additional IND and initiate an obesity program in 2021Altimmune to host a conference call today at 8:30 a.m. ET GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-

  • Altimmune to Present at the 2021 Jefferies Virtual Healthcare Conference
    GlobeNewswire

    Altimmune to Present at the 2021 Jefferies Virtual Healthcare Conference

    GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the 2021 Jefferies Virtual Healthcare Conference, being held June 1 - 4, 2021. Details on the Jefferies fireside chat presentation are as follows: Title: 2021 Jefferies Virtual Healthcare Conference Presenters: Vipin Garg, Ph.D., Chief Executive Officer Scot Roberts, Ph.D., Chief Scientific Officer Scott Harris, M.D., Chief Medical Officer Date/Time: Wednesday, June 2, 2021 at 11:30 am ET A webcast link to the fireside chat presentation will be accessible on the Events section of the Altimmune website. About Altimmune Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com. Investor & Media Contacts: Will Brown Stacey JurchisonChief Financial Officer Sr. Dir, Investor RelationsPhone: 240-654-1450 Phone : 410-474-8200wbrown@altimmune.com sjurchison@altimmune.com